Eton Pharmaceuticals (NASDAQ:ETON) Shares Break Above Fifty Day Moving Average - Should You Sell?

Key Points

• Q3 results substantially beat expectations: Revenue was $57.9 million, up 158% year over year, and non-GAAP EPS of $0.50 topped the $0.31 consensus estimate. Eton also said it surpassed a $200 million annualized revenue run rate five quarters ahead of schedule.
• Management raised its 2026 outlook: Revenue guidance increased to more than $175 million from more than $145 million, while adjusted EBITDA margin guidance rose to above 40% from above 35%.
• Shares moved above their 50-day moving average, and Canaccord Genuity and HC Wainwright raised their price targets to $80 while retaining Buy ratings. The article also reports insider sales totaling 79,166 shares over the last quarter.

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $54.80 and traded as high as $58.59. Eton Pharmaceuticals shares last traded at $56.46, with a volume of 1,269,987 shares.

Eton Pharmaceuticals News Roundup

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Q3 product sales reached a record $57.9 million, up 158% year over year. Eton reported diluted GAAP EPS of $1.06 and non-GAAP EPS of $0.50, and said it exceeded a $200 million annualized revenue run rate five quarters ahead of schedule. Eton Q3 results
• Positive Sentiment: Management raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to above 40%, from above 35%. The stronger forecast reinforces expectations for continued growth and improving profitability. Eton earnings and guidance
• Positive Sentiment: Canaccord Genuity and HC Wainwright both raised their price targets to $80 and maintained Buy ratings, signaling confidence in Eton’s prospects. Canaccord Genuity rating HC Wainwright rating
• Neutral Sentiment: Eton announced preliminary results from an ET-700 pilot study assessing copper absorption inhibition and gastrointestinal tolerability. The brief report does not provide enough detail to judge the findings’ significance for the pipeline. ET-700 pilot study update

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ETON shares. Weiss Ratings upgraded shares of Eton Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a report on Tuesday, September 22nd. HC Wainwright boosted their price target on Eton Pharmaceuticals from $70.00 to $80.00 and gave the company a "buy" rating in a research report on Friday. B. Riley Financial reiterated a "buy" rating and set a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Zacks Research upgraded shares of Eton Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 12th. Finally, Canaccord Genuity Group raised their price objective on shares of Eton Pharmaceuticals from $68.00 to $80.00 and gave the stock a "buy" rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Eton Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $77.00.

Eton Pharmaceuticals Trading Up 19.7%

The business's fifty day moving average is $54.80 and its two-hundred day moving average is $36.46. The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of 37.39 and a beta of 0.89.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.31 by $0.19. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. The business had revenue of $57.93 million for the quarter, compared to the consensus estimate of $41.98 million. Equities analysts anticipate that Eton Pharmaceuticals, Inc. will post 1.13 earnings per share for the current fiscal year.

Insider Activity at Eton Pharmaceuticals

In related news, Director Paul V. Maier sold 50,000 shares of the business's stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the completion of the sale, the director directly owned 59,745 shares of the company's stock, valued at $3,529,137.15. The trade was a 45.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider David Krempa sold 25,000 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the completion of the transaction, the insider owned 37,025 shares of the company's stock, valued at approximately $2,409,216.75. The trade was a 40.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 79,166 shares of company stock valued at $4,809,672 over the last quarter. Insiders own 16.49% of the company's stock.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Eton Pharmaceuticals in the 2nd quarter valued at about $68,629,000. Nantahala Capital Management LLC bought a new position in shares of Eton Pharmaceuticals during the second quarter worth about $42,569,426. Pillsbury Lake Capital LLC acquired a new position in Eton Pharmaceuticals in the second quarter worth approximately $14,015,083. Panoramic Capital LLC acquired a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $7,537,000. Finally, Cannell Capital LLC acquired a new stake in Eton Pharmaceuticals in the 2nd quarter valued at approximately $6,181,041. Institutional investors and hedge funds own 27.86% of the company's stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton's commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.